When was SciSparc founded?

SciSparc was founded in 2004 and raised its 1st funding round 17 years after it was founded.

Where is SciSparc located?

SciSparc is headquartered in United States.

How many employees does SciSparc have?

As of Jul 01, 2024, the latest employee count at SciSparc is 1.

Is SciSparc a funded company?

SciSparc is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Mar 05, 2021.

When was the latest funding round of SciSparc?

SciSparc's latest funding was a $***** Post IPO round on Feb 25, 2025, with participation from 0 investor.

Where does SciSparc rank among its competitors?

SciSparc ranks 6th amongst 23 active competitors, of which 3 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was SciSparc, which secured $4.2M in Feb, 2025.

Who are the top competitors of SciSparc?

SciSparc's top competitors include IGC Pharma, GW Pharma and MIRA Pharmaceuticals. Among them, SciSparc secured the most recent funding round in February, 2025.

SciSparc - 2026 Company Profile, Funding & Competitors

Company Details

Developer of cannabinoid technologies for central nervous system disorder treatments. The company focuses on creating therapeutics that modulate the central nervous system to mitigate adverse symptoms associated with these disorders. Its pipeline includes both FDA-approved compounds and new chemical entities believed to have strong potential for targeted conditions. The company enhances existing compounds with proprietary technologies to develop novel therapies. These therapies demonstrate heightened bioavailability, improved efficacy, lower dosage requirements, better safety profiles, and a reduction in side effects in clinical trials.

Website: scisparc.com
Social
Email ID: *****@scisparc.com
Phone Number: +972 **********

Key Metrics

Founded Year

2004

Location

United States

Stage

Public

Latest Funding Round

Post IPO, Feb 25, 2025, $*****

Ranked

6^th among 23 active competitors

Employee Count

1 as on Jul 01, 2024

Similar Companies

IGC Pharma & 24 more

Exit Details

Public

View SciSparc's full profile

SciSparc is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Scisparc Ltd CIN: 1611746 , United States, Active		-	-	-

SciSparc got listed on Jan 08, 2018.

Click here to take a look at SciSparc's IPO in detail

SciSparc has raised funding over 3 rounds. Its first funding round was on Mar 05, 2021.

Here is the list of recent funding rounds of SciSparc:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 25, 2025	5317598	Post IPO	6972099	2344508	9296686	7498344
Oct 13, 2023	9908227	Post IPO	7167333	4656550	9434311	4634916
Mar 05, 2021	8434781	Post IPO	9874353	5845371	8296235	5033999

Access funding benchmarks and valuations. Sign up today!

View details of SciSparc's funding rounds and investors

SciSparc's employee count trend

SciSparc has 1 employees as of Jul 24. Here is SciSparc's employee count trend over the years:

Uncover SciSparc's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SciSparc include IGC Pharma, GW Pharma and MIRA Pharmaceuticals. Here is the list of Top 10 competitors of SciSparc, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	IGC Pharma 2005, Potomac (United States), Public	Developer of therapies and artificial intelligence tools for Alzheimer’s disease	-	BRADBURY, Bradbury Group	59/100
2nd	GW Pharma 1998, Cambridge (United Kingdom), Acquired	Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy	$46.5M	New Leaf Capital, Bondeinvest.com & 6 others	50/100
3rd	MIRA Pharmaceuticals 2020, Baltimore (United States), Public	Developer of cannabinoid-based therapeutics for chronic pain and anxiety	-	-	49/100
4th	Hyasynth Bio 2014, Montreal (Canada), Series A	Developer of cannabinoid products intended to treat neurological disorders	$11M	Organigram, SOSV & 10 others	46/100
5th	Neurotech International 2016, Perth (Australia), Public	Developer of therapeutics for multiple paediatric neurological disorders	-	Transcontinental Group	45/100
6th	SciSparc 2004, United States, Public	Developer of cannabinoid technologies for central nervous system disorder treatments	-	-	45/100
7th	Avata Biosciences 2023, New York City (United States), Unfunded	Developer of cannabinoid medicines for neurological diseases	-	-	40/100
8th	NEUROPATHIX 2010, Doylestown (United States), Public	Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain	-	-	40/100
9th	Cannformatics 2017, San Francisco (United States), Unfunded	Developer of personalized medical cannabis treatment	-	-	38/100
10th	Pike Therapeutics 2019, Vancouver (Canada), Series A	Developer of psychedelic and cannabinoid therapeutics	$4.09M	-	34/100